Fiscal Year Ending March 2022 Financial Results Briefing

Thursday, June 9, 2022 PIOLAX, INC. (Code: 5988) Yukihiko Shimazu, President



Contents

I. Medium-Term Management Plan (FY22 to FY24)

- Business Environment
- Management Indicators
- Growth Strategies

(1. Automotive Business, 2. Medical Device Business)

- **II. Review of Capital Policy**
- **III. Promotion of ESG Management**



I. Medium-Term Management Plan



Vision, Basic Policies, And Management Strategies

As a pioneer creating elasticity, widely contribute to industries and society.

Basic Policies

Vision

- 1. Reform existing businesses.
- 2. Take on the challenge of new/next-generation businesses.
- 3. Strength the management foundation.
- 4. Actively invest for the future.
- 5. Promote ESG management.

Management Strategies

- 1. Product and customer strategy
- 2. Business strategy
- 3. Regional strategy
- 4. Growth investment strategy
- 5. Management capital strategy



Business Environment

Growth factors

 Continued increase in global automobile production

Global automobile production forecast (Unit: 1 million cars)

2021	2022	2023	2024	2030
84 -77	86- 83	92	97	105

- Accelerated shift to EVs
- Strengthen R&D capabilities responding to rapid market expansion.
- Acquire orders for CASE-compliant products. (A dedicated department is established.)
- Investment in growth foundations
- Improve productivity through IoT and DX.
- Relocate global production.
- Develop domestic infrastructure.
- Open a base in the EU (German office).
- Discovery of new businesses
 (A dedicated department is established.)

Risk factors


Red letters: Modified from the previous version

- Reduced production of major customers
- Decreased orders for existing Piolax products due to the shift to EVs
- Global economic downturn due to the COVID-19 crisis
- Material supply issues (Difficulties of procurement and soaring purchase costs)
- Rising labor costs
- Turmoil in global logistics
- Trade conflicts between the U.S. and China, and conflicts in Ukraine
- Foreign exchange fluctuation (Sharp yen depreciation)
- Impact of lockdown in Shanghai
- Rising energy costs
- Cyber attacks



Management Indicators - 1

Medium-term management plan (FY22-FY24) and review of previous plan (FY21-FY23)



Sales


The targets for FY21 were achieved, but the plan has been revised downward for FY22 and FY23 due to delayed recovery in automobile production and pressure on profits by higher material and logistics costs.

Achieving sales of ¥70 billion will be postponed one year to FY24, but the company is planning **a path of steady growth**.



All Rights Reserved, Copyright © PIOLAX, INC.





Operating profit


Management Indicators - 2: by Segment

Medium-term management plan for automobile-related business

Assumptions for FY24 sales plan (72 billion yen)

- Recovery of global car production by OEMs to the FY19 level
- Increase in sales per car by 10% for each new model
- Exchange rate: 1 USD = 120 JPY


Operating profit in the medium-term plan will be secured by the increase in marginal profit due to higher sales and streamlining.



Management Indicators - 2: by Segment

Medium-term management plan for medical device business

- Factors for downward revision: uncertainty about product supply due to component procurement risks, delayed launch of new products due to voluntary recall of in-house and imported products
- Impact of voluntary recall was reflected in FY21.
- Accelerate the introduction of new products from FY22 for early profit recovery.



Operating profit



Operating

profit ratio

20%

15%

10%

5%

0%

2024

I-1. Growth Strategy (Automotive Business)



Progress of Management Strategy: Automotive - 1


Management strategy and priority issues	Specific measures (FY21 actual)	Medium-term management plan initiatives
1.Product and customer strategy	Establish e-Products Development Dept. to respond to CASE	Accelerate response to CASE → Separate explanation
 Develop CASE parts and receive orders 	Non-Japanese OEM sales ratio: 14%	FY24: 16%
 Diversify customers and products 	Improve sales per car for new model Mainstay models: +20% (from FY18)	FY24: +10% (from FY21)
 Maximize profit margin for each product Achieve global high quality 	Build new quality assurance system	Improve quality through the new QA system
2.Business strategyDiscover new businesses	Establish MIRAI Business Dept. to discover a third business	Discover new businesses other than the existing automotive and medical devise businesses
 3.Regional strategy •Expand sales in North America and China •Expand profitability in ASEAN 	Expand sales in North America (U.S. and Mexico) and China Overseas sales ratio N.A. and China: 35% each	FY24 Maintain the current 35% in N.A. and China
 Make strategies for Continental Europe Strengthen regional management functions 	Open a representative office in Germany	New strategies for Continental Europe Further expand sales from non- Japanese (German) OEMs
	Achieve profitability in Indonesia Operating profit ratio in ASEAN and India: 11%	Improve profitability in ASEAN and India FY24 Operating profit ratio: 15%

Progress of Management Strategy: Automotive - 2

Management strategy and priority issues	Specific measures (FY21 actual)	Medium-term management plan initiatives
4.Growth investment strategyDevelop infrastructure in Japan	Start construction of new Moka Plant at full scale	FY23: Complete the phase 1 construction and start operation FY24: Start the phase 2 construction
 Strengthen R&D investment Promote DX 	Strengthen investing in CASE/ new businesses Ratio of R&D costs to sales: 1.2%	Strengthen investing in CASE/ new businesses FY24 :1.5%
5.Management capital strategy • Pursuit capital efficiency	Review capital policy and shareholder return	FY22 to FY-24 100% dividend payout ratio
 Return profits to shareholders Promote ESG management. 	 Promote ESG management. Set up Sustainability Committee Endorse TCFD and disclose information Disclose the target of carbon neutrality in 2050 Comply with the revised corporate governance code. 	 Promote ESG targets Promote measures toward carbon neutrality Improve TCFD disclosure Promote diversity Enhance governance



Expand sales of CASE-compliant products



Initiatives by Overseas Sites

Diversify products and customers (Enhance sales from non-Japanese OEMs)

Europe (U.K. and Germany) • Enhance sales from German OEMs using the representative office in (100 mil. Medium-term plan of sales of JPY) Germany overseas sites Consider production relocation in Europe 500 **ASEAN and India** India: Pune sales office opened in 2021 to enhance sales from Indian 475 **OEMs** Strengthen collaboration among sites in Thailand, India, and Indonesia Europe 345 China Enhance sales from Chinese OEMs ASEAN and India Production of ADAS sensor bracket has started for Guangzhou China Automobile Group Enhance sales from developing EV manufacturers North America Expand fastener business with Didi to EV parts business North American (U.S. and Mexico) • Expand production capacity of the U.S. and Mexico plants 0 Enhance sales from Big 3 2021 Actual 2024 •Enhance sales from VW and Hyundai

*Consolidated journal entries (internal transactions) are included in the numbers.



Infrastructure Development in Japan

Infrastructure development for future growth

1. New Moka Plant

Construction of phases 1 and 2

- Start of construction: Second half of FY22
- Full-scale operation: FY23
- Investment amount: 5.9 bil. JPY (FY22-FY24)
- Future Plan
 - FY24: Start of phase 2 construction
 - FY25: Start of operation (2nd stage)
 - FY30: Start of operation (3rd stage)

<Next-generation plant> Global Mother Plant

- Introduction of next-generation equipment and injection molding machines
- Automated lines through AI and IOT technologies
- Efficient production through DX
- Target: 200% increase in productivity in FY30
- Initiatives for carbon neutrality

2. Yokohama area renewal project

- Replan infrastructure development for the entire Yokohama area (Head Office and Yokohama Technical Center)
- Head office relocated in March 2022 due to aging of the building which is to be demolished in FY22
- Aim to improve productivity of indirect departments by establishing infrastructure based on work style reforms




Global Mother Plant which will publish the Piolax brand worldwide

- Respond to a wide variety of demands in the automotive industry through advanced production equipment and systems
- > Establish a highly profitable production system: 200% productivity
- Cutting-edge plant that is people-and environment-friendly



















Capital Investment for Sustainable Growth

<u>Capital investment for future growth</u> <u>centered on infrastructure development in Japan</u>

<u>FY22-24</u>

- Infrastructure development in Japan
 - New Moka Plant
 - Yokohama area renewal plan
- Expansion of overseas plants
- Capital investment in environmental measures


<Capital investment in environmental measures> Promote energy self-sufficiency through renewable energy by solar panels





PIOL/X

Capital investment and depreciation



I-2. Growth Strategy (Medical Device Business)




Progress of Management Strategy: Medical Device Business

Management strategy and priority issues	Specific measures (FY21 actual)	Medium-term management plan initiatives
1.Product and customer strategy	 Launch differentiated products to specific markets Minimally-invasive treatment such as "catheter for liver cancer" Strengthen development and launch of products that satisfy unmet needs 	Medium-term launch plan (Strategic new products) ■ Expand the market share in Japan of endoscope business FY21: 33% → FY24: 36%
2.Business strategyAccelerate development and lineup of new products Strengthen sales network in Japan3.Regional strategyStrengthen overseas expansion (Catheter for liver cancer, guide wire for digestive endoscope) •Asia: Develop Piolax brand •U.S. and Europe: Expand OEM		 Launch new products Sales plan billion JPY (FY22-FY24) Products to be launched New endoscope products Guide wires for digestive endoscope (Domestic OEM Business) Catheter for liver cancer in Asia



Introduction of New Medical Device

Expand market share with newly launched guide wire for digestive endoscope






II. Review of Capital Policy



For Creating Corporate Value - 1

Trends of ROIC and WACC

EVA spread remained negative for three consecutive years since 2019






For Creating Corporate Value - 2

Trends of PBR and EVA


PBR also declined significantly since 2019 when EVA spread turned negative

Aim for positive EVA spread and PBR greater than 1







Review of Capital Policy



(JPY)





Dividends and Dividend Payout Ratio


Note: Dividends have been adjusted to the value after the stock split (3-for-1 split of common stock) with Apr. 1, 2017 as the effective date.



All Rights Reserved, Copyright © PIOLAX, INC.

Financial Planning and Capital Policy

Cash allocation





III. Promote ESG Management




Applicable major SDGs		Materiality	Piolax ESG Vision 2030	Major initiatives
E	1 2.200000000000000000000000000000000000	 Energy Emission into the air Waste 	Corporate activities aiming for a carbon-free society and a recycling-oriented society	 Activities toward carbon neutral: reduction of greenhouse gas and energy consumption, etc.
S	3 5250AC 3 682504C 5 5000-000 5 6000-000 5 6000-0000 5 6000-00000 5 600000000 5 600000000000000	 Employment Occupational health and safety Diversity, equal opportunity 	Creation of a vibrant workplace where employees can work with a sense of security	 Promotion of work style reform Promotion of diversity Respect for human rights
G	8 828/15 8 828/15 10 450578 10 4505788 10 4505788 10 450578 10 450578 10 450578	 Compliance enhancement Governance enhancement 	 Fair and equitable transactions and improved trustworthy relationships Stable organizational management by enhanced governance 	 Compliance with modified corporate governance Enhanced compliance with risk management



Initiatives for climate change

Disclosing information based on TCFD recommendations

In March 2022, we announced our endorsement of the TCFD recommendations and disclosed information on our initiatives based on the TCFD recommendations. We will further strengthen our activities to enhance information disclosure.



Roadmap for carbon neutrality (CN)

Year 2030: 46% reduction Year 2050: 100% reduction * We aim for carbon neutrality by 2050 for Scopes 1 and 2. * Subject: Piolax and its domestic group companies * We will continue to analyze overseas group companies and further study in the whole group.

Please refer to our website for details.

Disclosure Based on the TCFD Recommendations: https://www.piolax.co.jp/resources/pdf/csr/PIOLAX_TCFD.pdf



Promoting diversity and health management

We regard the promotion of diversity as an important management issue. We will strive to create a comfortable working environment by improving our education system and reforming work styles so that human resources with diverse backgrounds can fully demonstrate their abilities and individuality.

In order to secure and utilize diverse human resources, we will consider initiatives to raise the ratio of female managers to 30% and actively recruit foreign and mid-career employees.

<u>Certification of the highest ranking (third stage) of "Eruboshi" as an</u> <u>outstanding company</u>

We will continue to make efforts to "expand the number of female managers" and "develop a workplace environment where anyone can work comfortably and play an active role".

<u>Certification as an "excellent health management corporation in 2022"</u> (large corporate division)

The source of vitality that supports our business environment is our "human assets or our employees and their families. As one of the most important management objectives, we will continue our support to promote mental and physical health and realize work-life balance of all employees.







Governance system: increasing the diversity of the Board of Directors

The Board of Directors if approved at our General Meeting of Shareholders on June 24, 2022 9 directors in FY21 \rightarrow 10 directors in FY22

<New system>

- Increase of female directors (+1)
 1 female (among 9 members) → 2 (among 10)
 Ratio of female directors: 20%
- 2) Increase of outside directors (+1)
 3 members → 4 (one retired, two newly appointed)

Ratio of outside directors: 40%


3) Increase of directors with skills relating to ESG/ sustainability (+2)

2 members \rightarrow 4

4) Increase of directors with skills relating to DX/IT (+1)

2 members \rightarrow 3

<Director skill matrix>






Governance system: establishment of Sustainability Committee

December 2021 Setup of Sustainability Committee Establishment of Sustainability Policy

Outline of Sustainability Committee

Members	Chairperson: President Members: Persons elected from the Board of Directors and assigned by the Chairperson
Secretariat	Management & Planning Group, Corporate Planning Group
Frequency of meetings	Meeting: 4 times a year (held as needed) Report to the Board of Directors: twice a year
Main topics	 Formulation of policies and materiality related to sustainability and ESG management Setting of targets and monitoring of progress Disclosure based on the TCFD Discussions in the committee are regularly reported to the Management Committee and the Board of Directors.

Corporate Governance System Chart





Notes on Handling This Document

The forward-looking statements contained in this document are based on information available to us at the time of publication. Please note that such statements are future projections at this time and contain risks and uncertainties and that actual results may significantly differ from the projections.



